UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

  Date of Report (Date of earliest event reported) September 20, 2021 

 

LEXARIA BIOSCIENCE CORP.

(Exact name of registrant as specified in its charter)

 

Nevada

 

000-52138

 

20-2000871

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

     

100 – 740 McCurdy Road, Kelowna, BC Canada

 

V1X 2P7

(Address of principal executive offices)

 

(Zip Code)

 

  Registrant’s telephone number, including area code (250) 765-6424 

  

(Former name or former address, if changed since last report.) 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange

on which registered

Common Stock, par value $0.001 per share

Warrants to Purchase Common Stock

 

LEXX

LEXXW

 

The Nasdaq Capital Market

The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

  

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

  

Item 7.01 Regulation FD 

 

On September 20, 2021, Lexaria Bioscience Corp. (“Lexaria”) was advised that an investor report (the “Report”) on Lexaria had been published by Zacks Investment Research, Inc. (“Zacks”) and disseminated via institutional investor platforms, retail investor platforms, social media and directly to their subscribers.

 

Lexaria has paid Zacks US$39,000 to provide analyst coverage for a year which includes an on-site visit, the preparation of the Report and four quarterly updates to the Report. The Report contains certain future projections for Lexaria’s revenues for the 2021, 2022 and 2023 fiscal years as well as valuations. A full copy of the Report is attached hereto as Exhibit 99.1.

 

Item 9.01 Financial Statements and Exhibits 

 

99.1

Zacks Investment Research Report

     

 

 2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

LEXARIA BIOSCIENCE CORP.

       
September 23, 2021 By: /s/ Chris Bunka

 

 

Chris Bunka  
    CEO, Principal Executive Officer  

 

 

3

Lexaria Bioscience (NASDAQ:LEXX)
Historical Stock Chart
From Nov 2021 to Dec 2021 Click Here for more Lexaria Bioscience Charts.
Lexaria Bioscience (NASDAQ:LEXX)
Historical Stock Chart
From Dec 2020 to Dec 2021 Click Here for more Lexaria Bioscience Charts.